X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
percutaneous coronary intervention (3) 3
thrombosis (3) 3
aged (2) 2
aspirin (2) 2
aspirin - administration & dosage (2) 2
aspirin - adverse effects (2) 2
cardiac & cardiovascular systems (2) 2
cardiovascular (2) 2
coronary artery disease - diagnosis (2) 2
coronary artery disease - mortality (2) 2
coronary artery disease - therapy (2) 2
double antiplatelet duration (2) 2
drug-eluting stent (2) 2
dual antiplatelet therapy (2) 2
female (2) 2
humans (2) 2
index medicus (2) 2
male (2) 2
middle aged (2) 2
myocardial-infarction (2) 2
percutaneous coronary angioplasty (2) 2
percutaneous coronary intervention - adverse effects (2) 2
platelet aggregation inhibitors - administration & dosage (2) 2
platelet aggregation inhibitors - adverse effects (2) 2
ticlopidine - administration & dosage (2) 2
ticlopidine - adverse effects (2) 2
ticlopidine - analogs & derivatives (2) 2
time factors (2) 2
treatment outcome (2) 2
6-month (1) 1
[ sdv ] life sciences [q-bio] (1) 1
[ sdv.mhep ] life sciences [q-bio]/human health and pathology (1) 1
[sdv.mhep]life sciences [q-bio]/human health and pathology (1) 1
[sdv]life sciences [q-bio] (1) 1
abridged index medicus (1) 1
acute coronary syndromes (1) 1
association (1) 1
bare-metal stents (1) 1
cardiology and cardiovascular medicine (1) 1
care and treatment (1) 1
clinical outcomes (1) 1
clinical-outcomes (1) 1
clopidogrel (1) 1
confidence intervals (1) 1
coronary artery disease - physiopathology (1) 1
coronary heart disease (1) 1
coronary restenosis - diagnosis (1) 1
coronary restenosis - etiology (1) 1
coronary restenosis - prevention & control (1) 1
coronary thrombosis - etiology (1) 1
coronary vessels (1) 1
coronary vessels - pathology (1) 1
coronary vessels - surgery (1) 1
drug administration schedule (1) 1
drug dosages (1) 1
drug therapy (1) 1
drug therapy, combination (1) 1
drug-eluting stents (1) 1
drug-eluting stents - adverse effects (1) 1
duration (1) 1
early termination of clinical trials (1) 1
efficacy (1) 1
europe (1) 1
everolimus (1) 1
follow-up (1) 1
france (1) 1
guidelines (1) 1
heart attacks (1) 1
hemorrhage - chemically induced (1) 1
hemorrhage - etiology (1) 1
hemorrhage - prevention & control (1) 1
hospitalization (1) 1
human health and pathology (1) 1
immunosuppressive agents - therapeutic use (1) 1
impact (1) 1
internal medicine (1) 1
kaplan-meier estimate (1) 1
life sciences (1) 1
middle east (1) 1
mortality (1) 1
myocardial infarction - etiology (1) 1
percutaneous coronary intervention - instrumentation (1) 1
percutaneous coronary intervention - methods (1) 1
percutaneous coronary intervention - mortality (1) 1
platelet reactivity (1) 1
pooled analysis (1) 1
postoperative complications - diagnosis (1) 1
postoperative complications - prevention & control (1) 1
proportional hazards models (1) 1
prospective studies (1) 1
prosthesis design (1) 1
risk (1) 1
risk factors (1) 1
safety (1) 1
sirolimus - analogs & derivatives (1) 1
sirolimus - therapeutic use (1) 1
society (1) 1
stent (1) 1
stents (1) 1
stroke (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 03/2015, Volume 65, Issue 8, pp. 777 - 786
Background The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the risk of... 
double antiplatelet duration | percutaneous coronary angioplasty | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | THROMBOSIS | BARE-METAL STENTS | FOLLOW-UP | RISK | PERCUTANEOUS CORONARY INTERVENTION | IMPACT | POOLED ANALYSIS | CLINICAL-OUTCOMES | PLATELET REACTIVITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Postoperative Complications - prevention & control | Male | Hemorrhage - prevention & control | Aspirin - administration & dosage | Drug-Eluting Stents - adverse effects | Middle East | Early Termination of Clinical Trials | Coronary Restenosis - diagnosis | Coronary Artery Disease - physiopathology | Time Factors | Aspirin - adverse effects | Percutaneous Coronary Intervention - methods | Hemorrhage - etiology | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Everolimus | Coronary Restenosis - etiology | Platelet Aggregation Inhibitors - adverse effects | Coronary Vessels - pathology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Europe | Coronary Restenosis - prevention & control | Treatment Outcome | Coronary Artery Disease - mortality | Postoperative Complications - diagnosis | Ticlopidine - analogs & derivatives | Coronary Artery Disease - therapy | Coronary Artery Disease - diagnosis | Coronary Vessels - surgery | Aged | Percutaneous Coronary Intervention - adverse effects | Aspirin
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 06/2017, Volume 10, Issue 12, pp. 1202 - 1210
Journal Article
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 8, pp. 777 - 786
Abstract Background The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the... 
Cardiovascular | Internal Medicine | double antiplatelet duration | percutaneous coronary angioplasty | Coronary heart disease | Care and treatment | Stent (Surgery) | Aspirin | Stroke | Heart attacks | Mortality | Hospitalization | Thrombosis | Clinical outcomes | Confidence intervals | Coronary vessels | Surgery | Drug therapy | Acute coronary syndromes | Stents | Drug dosages | Veins & arteries
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.